Banco Santander S.A. Sells 11,523 Shares of Pfizer Inc. (NYSE:PFE)

Banco Santander S.A. lessened its position in Pfizer Inc. (NYSE:PFE) by 3.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 310,594 shares of the biopharmaceutical company’s stock after selling 11,523 shares during the quarter. Banco Santander S.A.’s holdings in Pfizer were worth $10,137,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in shares of Pfizer by 0.5% in the 4th quarter. State Street Corp now owns 291,791,099 shares of the biopharmaceutical company’s stock worth $11,432,375,000 after acquiring an additional 1,521,665 shares during the last quarter. Capital World Investors lifted its holdings in shares of Pfizer by 13.4% in the 4th quarter. Capital World Investors now owns 188,715,390 shares of the biopharmaceutical company’s stock worth $7,393,867,000 after acquiring an additional 22,232,056 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Pfizer by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 89,043,762 shares of the biopharmaceutical company’s stock worth $3,482,382,000 after acquiring an additional 1,630,039 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Pfizer by 4.9% in the 4th quarter. Bank of New York Mellon Corp now owns 59,763,050 shares of the biopharmaceutical company’s stock worth $2,341,517,000 after acquiring an additional 2,783,991 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Pfizer in the 4th quarter worth about $2,326,225,000. Hedge funds and other institutional investors own 69.91% of the company’s stock.

PFE has been the subject of several analyst reports. Royal Bank of Canada restated a “buy” rating and issued a $44.00 target price on shares of Pfizer in a report on Monday, April 27th. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $40.00 price target on the stock. in a research note on Monday, May 4th. Barclays raised their price target on shares of Pfizer from $36.00 to $37.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 29th. Standpoint Research raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, February 27th. Finally, Morgan Stanley reduced their price target on shares of Pfizer from $43.00 to $36.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 2nd. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Pfizer currently has an average rating of “Hold” and an average price target of $41.28.

NYSE PFE traded up $0.24 during trading on Friday, reaching $37.50. 14,885,114 shares of the company’s stock traded hands, compared to its average volume of 22,354,300. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.02 and a quick ratio of 0.78. The firm has a market cap of $206.97 billion, a price-to-earnings ratio of 13.39, a price-to-earnings-growth ratio of 2.72 and a beta of 0.71. The company’s 50 day simple moving average is $36.51 and its two-hundred day simple moving average is $36.84. Pfizer Inc. has a 12-month low of $27.88 and a 12-month high of $44.56.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, April 28th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.09. The business had revenue of $12.03 billion for the quarter, compared to the consensus estimate of $11.38 billion. Pfizer had a net margin of 31.17% and a return on equity of 25.76%. The company’s revenue for the quarter was down 8.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.85 EPS. Research analysts expect that Pfizer Inc. will post 2.81 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 8th will be given a $0.38 dividend. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.05%. The ex-dividend date of this dividend is Thursday, May 7th. Pfizer’s payout ratio is currently 51.53%.

In other news, major shareholder Pfizer Inc acquired 312,500 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were purchased at an average price of $16.00 per share, with a total value of $5,000,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Douglas M. Lankler sold 65,000 shares of Pfizer stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $37.85, for a total transaction of $2,460,250.00. Following the completion of the transaction, the executive vice president now directly owns 135,375 shares in the company, valued at approximately $5,123,943.75. The disclosure for this sale can be found here. 0.08% of the stock is owned by insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: How to Trade Using Analysts Ratings

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.